Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.31 |
| ▸ | CTSS | P25774 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.30 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.30 |
| ▸ | MCTS1 | Q9ULC4 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.30 |
| ▸ | GRM5 | P41594 | 1/20 | 0.30 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26124981 | 0.93 | IDO1 (0.33) | IDO1 | |
| SCHEMBL21543198 | 0.81 | SLC16A3 (0.32) | SLC16A3SLC16A1MCTS1HTT | |
| SCHEMBL21543072 | 0.79 | GRM5 (0.30) | GRM5GRM1 | |
| SCHEMBL4821504 | 0.78 | SMYD2 (0.33) | HTT | |
| SCHEMBL2598798 | 0.76 | LTA4H (0.41) | ALDH1A1HTTGRM5GRM1 | |
| SCHEMBL4822404 | 0.75 | PDCD1 (0.34) | HTT | |
| SCHEMBL9566297 | 0.75 | IDO1 (0.33) | IDO1HTT | |
| SCHEMBL9258712 | 0.74 | CRHBP (0.33) | IDO1SLC16A3SLC16A1MCTS1ALDH1A1 | |
| SCHEMBL23201480 | 0.74 | SMYD2 (0.33) | HTT | |
| SCHEMBL27610986 | 0.74 | IDO1 (0.51) | IDO1MAPTMEN1ALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250381187-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. (US) | 2025-12-18 | — | — | US | disclosed |
| US-12440491-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2025-10-14 | — | — | US | disclosed |
| US-12083121-B2 | Substituted piperazines as KRAS G12C inhibitors | AMGEN INC. (US) | 2024-09-10 | — | — | US | disclosed |
| US-20240050430-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2024-02-15 | — | — | US | disclosed |
| EP-3788038-B1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC (US) | 2023-10-11 | — | — | EP | disclosed |
| US-11766436-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-11766436-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-20220395504-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2022-12-15 | — | — | US | disclosed |
| US-20220175782-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2022-06-09 | — | — | US | disclosed |
| US-11285156-B2 | Substituted piperazines as KRAS G12C inhibitors | AMGEN INC. (US) | 2022-03-29 | — | — | US | disclosed |
| US-11090304-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2021-08-17 | — | — | US | disclosed |
| EP-3807276-A2 | KRAS G12C INHIBITORS ENCOMPASSING A PIPERAZINE RING AND USE THEREOF IN THE TREATMENT OF CANCER | Amgen Inc. (US) | 2021-04-21 | — | — | EP | disclosed |
| EP-3788038-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | Amgen Inc. (US) | 2021-03-10 | — | — | EP | disclosed |
| US-20190343838-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2019-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11285156-B2 | Substituted piperazines as KRAS G12C inhibitors | KRAS, NRAS, HRAS | IDO1 4294/4885RIPK1 941/4885CTSS 2784/4885 |
| US-20190343838-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | IDO1 4527/4885RIPK1 957/4885CTSS 1926/4885 |
| US-11090304-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | IDO1 4527/4885RIPK1 957/4885CTSS 1926/4885 |
| US-20250381187-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | IDO1 4527/4885RIPK1 957/4885CTSS 1926/4885 |
| US-12083121-B2 | Substituted piperazines as KRAS G12C inhibitors | KRAS, NRAS, HRAS | IDO1 4294/4885RIPK1 941/4885CTSS 2784/4885 |
| US-12440491-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | IDO1 4527/4885RIPK1 957/4885CTSS 1926/4885 |
| US-20220395504-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | IDO1 4527/4885RIPK1 957/4885CTSS 1926/4885 |
| US-20240050430-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | IDO1 4527/4885RIPK1 957/4885CTSS 1926/4885 |
| US-20220175782-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | IDO1 4506/4885RIPK1 933/4885CTSS 1849/4885 |
| US-11766436-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | IDO1 4527/4885RIPK1 957/4885CTSS 1926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.